Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference9%
- Check25 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0.SummaryDifference0.2%
- Check32 days agoChange DetectedUpdated the page to include current date 2025-09-16 and a new 2025-09-12 Study Status; removed an older date 2025-06-10. No major changes to core content or pricing are implied.SummaryDifference0.9%
- Check39 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, signaling a minor patch; the Back to Top link has been removed. No other substantive changes to core content, pricing, stock, or time-related information were introduced.SummaryDifference0.5%
- Check46 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.5%
- Check53 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, as well as numerous updates to study status documentation spanning several years. However, several location-related terms have been removed.SummaryDifference55%
Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.